Genfit Thinks Intercept’s Lead In NASH Not As Wide As Perceived

 
• By Joseph Haas
  
liver
Genfit should be the second company to file an NDA in NASH
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business